Tesamorelin - 10 mg (Growth Hormone–Releasing Peptide Analog)

1. Pituitary Activation & GH Secretion

Tesamorelin binds to GHRH receptors on pituitary somatotrophs, activating cyclic-AMP signaling that:

• Stimulates pulsatile GH release
• Enhances IGF-1 (Insulin-like Growth Factor 1) synthesis in the liver and tissues
• Promotes protein synthesis and cellular growth
• Supports tissue repair and regeneration

Unlike direct GH administration, Tesamorelin encourages physiological GH release patterns, maintaining hormonal balance.

2. Fat Metabolism & Visceral Reduction

In metabolic research, Tesamorelin demonstrates powerful lipolytic effects through GH-mediated activation of hormone-sensitive lipase (HSL) and IGF-1 signaling. It contributes to:

• Reduction of visceral (abdominal) adipose tissue
• Enhanced lipid oxidation and energy mobilization
• Improved triglyceride and cholesterol profiles
• Increased lean-mass preservation

These actions make Tesamorelin a leading peptide for studying fat redistribution, metabolic optimization, and aging metabolism.

3. Muscle & Tissue Regeneration

By boosting GH and IGF-1 levels, Tesamorelin supports:

• Muscle-fiber repair and myocyte proliferation
• Collagen synthesis for skin, joint, and tendon resilience
• Cellular regeneration following injury or stress
• Enhanced sleep quality and recovery response

Research indicates improved body composition, vitality, and tissue elasticity through the GH/IGF-1 axis.

4. Cognitive & Neuroprotective Effects

Emerging research suggests Tesamorelin may positively influence cognitive function by:

• Supporting neuronal plasticity via IGF-1 signaling
• Reducing oxidative stress and inflammatory markers
• Promoting mitochondrial health in neural tissue

These findings make it a valuable peptide for neuroendocrine and longevity-focused studies.

• GH/IGF-1 axis and endocrine-function studies
• Body-composition and fat-metabolism research
• Muscle-recovery and performance models
• Skin-elasticity and tissue-regeneration studies
• Cognitive and longevity-mechanism exploration

Tesamorelin -10 mg Lyophilized Peptide Powder

Tesamorelin (10 mg) — Research Dosage Guidance
Reconstitution (Mixing)

• Add 2 ml Bacteriostatic Water to the vial
• Roll gently between palms (do not shake)
• Store reconstituted vial in the refrigerator (2–8 °C)

Concentration Calculation

10 mg ÷ 2 ml = 5 mg per ml

Every 10 insulin units (0.1 ml) = 0.5 mg (500 mcg)

Core Dosage Guidelines

For fat-loss, body-composition improvement, and growth-hormone stimulation research

Standard research protocol: 1 mg daily

Timing: Inject once daily, preferably at night before sleep, on an empty stomach (≥2 hours after food)

Alternate schedule: Every other day or 5 days per week for maintenance

Administration: Subcutaneous injection (abdomen or thigh)

Injection sites: Rotate regularly

Syringe Measurement Guide
Dose    Volume (ml)    Insulin Units
250 mcg    0.05 ml    5 units
500 mcg    0.10 ml    10 units
1 mg (recommended)    0.20 ml    20 units

Reference: Every 10 units (0.1 ml) = 500 mcg Tesamorelin

Targeted Research Protocols (Different Situations)
1.⁠ ⁠Abdominal / Visceral Fat Reduction Research

• (Central fat, metabolic optimization models)
• Dose: 1 mg
• Frequency: Once daily
• Timing: Nighttime (pre-sleep)
• Duration: 8–12 weeks
• Notes: Best-studied use case for Tesamorelin

2.⁠ ⁠Body Recomposition & Lean-Mass Preservation

• (Fat loss with muscle preservation)
• Dose: 1 mg
• Frequency: 5–7× weekly
• Duration: 10–12 weeks
• Notes: Maintain adequate protein intake in research models

3.⁠ ⁠Growth Hormone & IGF-1 Pathway Research

• (GH pulse amplification, recovery models)
• Dose: 500 mcg – 1 mg
• Frequency: Once daily
• Timing: Evening or pre-sleep
• Duration: 8–12 weeks
• Notes: Lower doses may still produce measurable GH effects

4.⁠ ⁠Recovery, Sleep & Skin-Health Research

• (Tissue repair, sleep architecture, dermal quality)
• Dose: 500 mcg – 1 mg
• Frequency: 3–5× weekly
• Timing: Nighttime preferred
• Duration: 6–10 weeks
• Notes: Reduced frequency often sufficient

5.⁠ ⁠Maintenance / Long-Term Support Research

• Dose: 500 mcg
• Frequency: Every other day or 3× weekly
• Duration: Ongoing after a full cycle
• Notes: Helps sustain GH support with reduced exposure

Cycle Duration

• Typical cycle: 8–12 weeks
• Maintenance phase: 500 mcg daily or every other day
• Breaks: Recommended between extended research cycles

Key Research Benefits

• Promotes endogenous growth-hormone release
• Supports IGF-1 production
• Encourages fat loss, especially abdominal fat
• Assists muscle definition and recovery
• May enhance sleep quality and skin health

Important Notes

Always use sterile needles and alcohol swabs

Do not reuse or share needles

Store reconstituted peptide at 2–8 °C

For research use only

Tesamorelin Who Should Use With Caution or Avoid (Research Contexts)

Tesamorelin is a growth-hormone–releasing peptide that activates the GH/IGF-1 axis. Use caution or avoid in the following research contexts:

Active cancer or tumor-bearing models (GH/IGF-1 signaling may accelerate growth)

Pregnancy or lactation models (no safety data available)

Uncontrolled diabetes or severe insulin resistance (GH may elevate blood glucose)

Severe edema, heart failure, or kidney disease models (risk of fluid retention)

Pituitary disorders or acromegaly models (risk of GH-axis overstimulation)

Carpal tunnel syndrome or neuropathy-prone models (monitor for symptom exacerbation)

Tesamorelin is a potent GHRH analog supporting research on fat metabolism, muscle preservation, and growth-hormone physiology. Side effects are typically mild and reversible, most commonly temporary fluid retention, joint discomfort, fatigue, or small itchy welts at the injection site. Proper dilution, rotation of sites, and gradual dose introduction ensure optimal tolerance and consistent research outcomes.